Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...
Please provide your email address to receive an email when new articles are posted on . Patients with pathologic complete response after neoadjuvant systemic therapy remained disease-free at 5 years ...
Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...
Neoadjuvant chemotherapy did not improve disease-free survival compared with upfront surgery in patients with locally advanced colon cancer in a randomized trial. However, neoadjuvant chemotherapy did ...
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer Neoadjuvant approaches for HER2-positive breast ...
Long-term data from a prospective phase 2 trial show neoadjuvant cisplatin-based chemotherapy before nephroureterectomy provides durable survival benefits in high-risk, nonmetastatic UTUC. Neoadjuvant ...
The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...
MedPage Today on MSN
Low Breast Cancer Recurrence Rate With Radiotherapy Tailored to Nodal Response
Locoregional recurrence rate of 2.9% overall with no variation across node-defined risk gr ...
The use of neoadjuvant chemotherapy failed to improve disease-free survival (DFS) over upfront surgery in patients with locally advanced colon cancer, a phase III randomized trial showed. Among 248 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results